Rep. Eliot Engel (D-NY) made a brief appearance Tuesday at a Congressional briefing, hosted by several TB advocacy organizations, highlighting tuberculosis and its continuation as a global health threat. He called the fact that TB hasn’t been eradicated “a sin,” and then briefly announced the newly formed U.S. House of Representatives TB Elimination Caucus – […]
Otsuka Pharmaceuticals is the top private funder of tuberculosis (TB) research and drug development in the world. Last year, Otsuka established a Geneva-based subsidiary – Otsuka SA – to serve as “the company’s central operations for developing and implementing public health policies and corporate social responsibility programs in connection with its global TB program,” according to the company’s website.
As part of our reporting in advance of World TB Day on Saturday (March 24), Science Speaks interviewed Patrizia Carlevaro, PhD, the leader of Otsuka SA, to discuss Otsuka’s latest research to address drug-resistant forms of TB, the world’s emerging tuberculosis “hotspots,” and other efforts by the subsidiary organization to tackle TB.
HIV
The following is a guest post By Sharon Weir, Ph.D. of MEASURE Evaluation For almost 35 years, HIV/AIDS has been a household word across the globe. […]
Tuberculosis
The following is a guest post by Stephanie Mullen, DrPH, and Jim Thomas, PhD of MEASURE Evaluation USAID announced September 26 a new approach to fight […]
Research & Development
A trial to test the safety of, and immune response prompted by, the latest candidate for a vaccine to protect against Zika virus infection has begun […]
Policy
Estimate exceeds previous estimates by more than $20 billion Deaths from non-Ebola causes contributed to highest West Africa outbreak costs, authors say During the 2013 to […]